Clontech
login | register | order now | view cart | feedback
Products
Cell Biology & Epigenetics


Products >  Cell_Biology_and_Epigenetics >  Cancer_and_Inflammation >  CD3

Anti-CD3 Monoclonal Antibody, Mouse

The anti-CD3 monoclonal antibody (OKT3) recognizes CD3, a human glycoprotein and member of the Ig superfamily that is primarily expressed on T cells, some NKT cells, and thymocytes during T cell differentiation. Binding of an anti-CD3 monoclonal antibody to CD3 stimulates T cell activation. Anti-CD3 antibodies (the OKT3 clone in particular) are used to expand T cells in culture for use in adoptive immunotherapy. This product is manufactured as a quality-assured product according to guidelines for Good Manufacturing Practice (GMP) for Investigational Products, and is therefore suitable for ex vivo cell culture processing and gene therapy studies. T cell expansion can be further enhanced by co-stimulation with RetroNectin (GMP).

  At-A-Glance   Documents   Images & Data

Features

  • GMP-grade, animal-derived component free, anti-CD3 mouse monoclonal antibody.
  • Clinical grade Anti-CD3 mAb (GMP) can be used for ex vivo cell culture processing (investigational use only)—please complete and return this form prior to purchase.
  • Can be used in combination with RetroNectin (GMP) to enhance T cell expansion efficiency in culture.

Applications

  • CIK (Cytokine-Induced Killer) cell expansion.
  • T lymphocyte expansion for adoptive immunotherapy.

Source

  • Mouse hybridoma cells

Purity

  • >95% by HPLC

Storage

  • 2–8°C

Notes

  • This product is for research use and ex vivo applications.

Form

  • 1.0 mg/ml sterilized solution

References

Citations related to anti-CD3 antibodies in adoptive immunotherapy:

  1. Kawamura, A. Jr, Sekine, T., Sekiguchi, M., Yanoma, S., Kaneko, A., Haneda, T., Moriya, Y., Hayasaka, K., Kakizoe, T. (2000) Six-year disease-free survival of a patient with metastatic eyelid squamous cell carcinoma and colon adenocarcinoma after repeated postoperative adoptive immunotherapy. Jpn J Clin Oncol. 30(6):267–271.
  2. Chono, H., Goto, Y., Yamakawa, S., Tanaka, S., Tosaka, Y., Nukaya, I., Mineno, J. (2011) Optimization of lentiviral vector transduction into peripheral blood mononuclear cells in combination with the fibronectin fragment CH-296 stimulation. J Biochem. 149(3):285–292.
  3. Ciceri, F., Bonini, C., Stanghellini, M. T., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., Pescarollo, A., Servida, P., Magnani,Z., Perna, S. K., Valtolina, V., Crippa, F., Callegaro, L., Spoldi, E.,Crocchiolo, R., Fleischhauer, K., Ponzoni, M., Vago, L., Rossini, S., Santoro, A., Todisco, E., Apperley, J., Olavarria, E., Slavin, S., Weissinger, E. M.,Ganser, A., Stadler, M., Yannaki, E., Fassas, A., Anagnostopoulos, A., Bregni, M., Stampino, C. G., Bruzzi, P., Bordignon, C. (2009) Infusion of suicide-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomized phase I-II study. Lancet Oncol. 10(5):489–500.
  4. Dudley, M. E., Wunderlich, J. R., Yang, J. C., Sherry, R. M., Topalian, S. L., Restifo, N. P., Royal, R. E., Kammula, U., White, D. E., Mavroukakis, S. A., Rogers, L. J.,Gracia, G. J., Jones, S. A., Mangiameli, D. P., Pelletier, M. M., Gea-Banacloche, J., Robinson, M. R., Berman, D. M., Filie, A. C., Abati, A., Rosenberg, S. A. (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 23(10):2346–2357.
  5. Lamers, C. H., Willemsen, R. A., Luider, B. A., Debets, R., Bolhuis, R. L. (2002) Protocol forgene transduction and expansion of human T lymphocytes for clinical immunogenetherapy of cancer. Cancer Gene Ther. 9(7):613–623.
  6. Li, J. J., Gu, M. F., Pan, K., Liu, L. Z., Zhang, H., Shen, W. X., Xia, J. C. (2012) Autologous cytokine-induced killer cell transfusion in combination with gemcitabine plus cisplatin regimen chemotherapy for metastatic nasopharyngeal carcinoma. J Immunother. 35:189–195.
  7. Dodo, K., Chono, H., Saito, N., Tanaka, Y., Tahara, K., Nukaya, I., Mineno, J. (2014) An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking. PLoS ONE. 9(1):e86275.

 
 
Products
Cat. # Product Contents Size Price License Units Select
T210 Anti-CD3 mAb GMP grade 1 mg/1 mL $1,485.00 License Statements
 

 

Recommended Products
Cat. # Product Contents Size Price Units Select
T201 RetroNectin® GMP grade 2.5 mg $1,442.00
 
 
 

Takara Bio USA is a Takara Bio Company © 2017 Privacy Policy | Terms & Conditions | Terms of Use